Search Results - "Cilissen, C"

In a 5-Day Monotherapy Trial, MK-8408 Demonstrates Potent Antiviral Activity and Improved Resistance Profile in HCV Patients with Genotypes 1, 2, and 3 Infections by Asante-Appiah, E, Marshall, W, Gane, E, Popa, S, McMonagle, P, Curry, S, Maganti, L, Gao, W, Garrett, G, Cilissen, C, De Lepeleire, I, Black, T, Hazuda, D, Butterton, J

Get full text

Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men by Caro, L, Hoon, J, Depré, M, Cilissen, C, Miller, J, Gao, W, Panebianco, D, Guo, Z, Troemel, SL, Anderson, MS, Uemura, N, Butterton, J, Wagner, J, Wright, DH

“…Vaniprevir is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease. The aim of these double‐blind, placebo‐controlled phase I studies was to evaluate…”
Get full text

Energy metabolism in women during short exposure to the thermoneutral zone by Westerterp-Plantenga, M.S, van Marken Lichtenbelt, W.D, Cilissen, C, Top, S

“…Ambient temperature has been shown to affect energy metabolism in field situations. Therefore, we assessed the effect of a short exposure to the thermoneutral…”
Get full text

THU-222 - In a 5-Day Monotherapy Trial, MK-8408 Demonstrates Potent Antiviral Activity and Improved Resistance Profile in HCV Patients with Genotypes 1, 2, and 3 Infections by Asante-Appiah, E., Marshall, W., Gane, E., Popa, S., McMonagle, P., Curry, S., Maganti, L., Gao, W., Garrett, G., Cilissen, C., De Lepeleire, I., Black, T., Hazuda, D., Butterton, J.

Get full text